<DOC>
	<DOCNO>NCT01062867</DOCNO>
	<brief_summary>Title : First administration man Org 25435 , new intravenous anaesthetic . Protocol : 12.4.104 Clinical Phase : Phase I Study Site : Phase I Clinical Trials Unit Ltd Old Convent Notre Dame 119 Looseleigh Lane Plymouth PL6 5HH United Kingdom Objectives : To assess safety , tolerability , preliminary pharmacokinetics efficacy Org 25435 intravenous anaesthetic . Study Design : Sequential study intravenous anaesthetic young healthy male , eight dose level . Study Drug : Org 25435 , water soluble intravenous anaesthetic . Subjects : Up 47 healthy male volunteer , age 18-40 year . Evaluations : Tolerability , adverse event , EEG effect , cardiovascular effect , electrocardiogram ( ECG ) , excitatory phenomenon , respiratory effect , laboratory safety blood analysis , pharmacodynamic pharmacokinetic measurement .</brief_summary>
	<brief_title>First Administration Man Of Org 25435 New Intravenous Anesthetic</brief_title>
	<detailed_description>Synopsis Trial Number 12.4.104 Trial Title First administration man Org 25435 new intravenous anesthetic Trial Center Phase 1 Clinical Trials Unit Limited , 119 Looseleigh Lane , Derriford , Plymouth PL6 5HH Publication Studied Period The first subject screen 04/01/2000 final subject complete follow 24/03/2000 . Phase Development Phase I ( First Man ) Objectives To assess safety , tolerability efficacy Org 25435 intravenous anesthetic obtain preliminary pharmacodynamic pharmacokinetic detail Org 25435 . Methodology Sequential rise dose study intravenous anesthetic young healthy male , eight dose level . Number Subjects 19 healthy male volunteer include dose escalation part study additional 7 volunteer participate Target Controlled Infusion ( TCI ) part study . Diagnosis Main Criteria Inclusion Inclusion criterion : Good physical mental health : absence clinically relevant medical history ; Clinically acceptable hematology clinical chemistry result ; Hemoglobin &gt; 13.5 g/dl ; Normal ECG ; Diastolic blood pressure 60 90 mmHg inclusive ; Normal cardiac morphology demonstrate echocardiography ; Satisfactory cardiovascular response exercise , measure Bruce Protocol , subject must complete Bruce stage 5 ; Aged 18 35 year inclusive ; Body mass index ( BMI ) 19 27 inclusive , weight 65 100 kg inclusive ; Negative hepatitis screen ; Non-smoker least 6 month ; Previous experience general anesthesia problem report ; Willingness give write informed consent ; Ability communicate well Investigators . Investigational Product Dose Mode Administration Batch Number 1 vial 200mg Org 25435 / 10ml solvent reconstitution Intended dos : 0.25 , 0.5 , 1.0 , 2.0 , 3.0 , 4.0 , 5.0 6.0 mg/kg Intravenous 9J521 Duration Treatment Dose Escalation phase : Each study treatment consist intravenous infusion Org 25435 , give Infusion pump exactly 1 minute . Target Controlled Infusion phase : Each study treatment consist intravenous infusion Org25435 give computer-controlled infusion 30 minute . Criteria Evaluation Tolerability , adverse event , EEG effect , cardiovascular effect , electrocardiogram ( ECG ) , excitatory phenomenon , respiratory effect , laboratory safety blood analysis , pharmacodynamic pharmacokinetic measurement . Efficacy Induction phenomenon ; time cessation speech , eye closure , loss eyelash reflex , eye open command , limb movement command syringe drop . Other Induction phenomenon ; pain injection , sign histamine release , excitatory phenomenon , respiratory depression , apnea . Recovery phenomenon ; nausea / vomiting , delirium , shiver , disturbed psychomotor function , eye opening command , spontaneous respiration , adequate respiration , move limbs command , increase saliva production . Statistical Methods Formal statistical method appropriate small pilot investigative study group size comprise 5 less subject . All data collect present summarized accord investigation type ( Dose Escalation TCI ) .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Anesthetics , Intravenous</mesh_term>
	<criteria>Good physical mental health : Absence clinically relevant medical history Clinically acceptable hematology clinical chemistry result Hemoglobin &gt; 13.5 g/dl Normal ECG Diastolic blood pressure 60 90 mmHg inclusive Normal cardiac morphology demonstrate echocardiography Satisfactory cardiovascular response exercise , measure Bruce Protocol , subject must complete Bruce stage 5 Aged 18 35 year inclusive Body mass index ( BMI ) 19 27 inclusive , weight 65 100 kg inclusive Negative hepatitis screen Nonsmoker least 6 month Previous experience general anesthesia problem report Willingness give write informed consent Ability communicate well Investigators . Females History evidence clinically significant cardiovascular , respiratory , endocrine , renal , hepatic , neurological psychiatric disease . History familial presence malignant hyperthermia . Presence condition likely affect normal kinetics study drug . Requirement prescribed medication . Use concomitant medication 5 day prior dose . General anaesthesia within previous 3 month . History clinically significant allergy hypersensitivity drug . History clinically significant head injury . History febrile convulsion . Known history human immunodeficiency virus ( HIV ) infection . Use investigational drug within previous three month . Previous administration investigational intravenous anaesthetic drug . Previous administration Org 25435 within study . History alcohol / drug abuse . Average consumption 20 unit alcohol week . Subjects smoke smoke within past 6 month . Inability communicate Investigators reason . Donation blood within one month study , intention donate blood within one month follow study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Anaesthetic</keyword>
</DOC>